A potential new way to fight obesity-related illness has
been uncovered, thanks to serendipitous research led by investigators at the
Case Western Reserve University School of Medicine.
An essential antioxidant, vitamin E had been shown by recent
studies to alleviate some symptoms of nonalcoholic steatohepatitis (NASH) in
human patients, suggesting that there is a link between adequate vitamin E
levels and liver disease.
While studying the effect of vitamin E deficiency on the
central nervous system of mice, the research came across those with advanced
stages of nonalcoholic steatohepatitis.
To test this hypothesis, the team studied a mouse that was
engineered to lack a protein that regulates the levels of vitamin E in the
body. As expected, they observed increased oxidative stress, fat deposition and
other signs of liver injury in the mice. Supplementation with vitamin E averted
the majority of NASH-related symptoms in these animals, confirming the
relationship between vitamin E deficiency and liver disease.
The precise effects of vitamin E on health have previously
been difficult to ascertain, though its antioxidative properties were suggested
to offer some protection from a variety of well-known maladies, including heart
disease, cancer and neurological diseases such as Alzheimer’s and Lou Gehrig’s
disease (amyotrophic lateral sclerosis, or ALS).
“These findings may have a significant impact on public
health as the vast majority of adults in the United States do not consume the
amount of vitamin E recommended by the National Institute of Medicine.” says Danny Manor, an
associate professor at the Case Western Reserve University School of Medicine.
For adults, the recommended dietary allowance of vitamin E
is 15 milligrams a day. Vegetable oils, nuts and seeds, leafy greens and
fortified cereals commonly contain vitamin E. “Simple and affordable dietary
intervention may benefit people at risk for this debilitating disease,” Manor
says.
There is currently no treatment for NASH, making it one of
the most common reasons for liver transplantation.
Manor and colleague Varsha Thakur presented the group’s
findings at the annual meeting of the American Society for Biochemistry and
Molecular Biology, held in conjunction with the Experimental Biology 2013
meeting in Boston.
###
The above story is based on the April 23, 2013 news release
by American
Society for Biochemistry and Molecular Biology (ASBMB)
NASH is a common complication of obesity characterized by
fat accumulation, oxidative stress and inflammation in the liver. It is the
most severe form of nonalcoholic fatty liver disease and is a major cause of
tissue scarring known as cirrhosis that leads to liver failure and may progress
to liver cancer. There
is currently no treatment for NASH, making it one of the most common reasons
for liver transplantation.
If you want to follow this blog by email free of charge, please submit your email address below or on the top right hand side of this page.
No comments:
Post a Comment